---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-049411"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:14:52.848496+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics Q2 FY2025 net loss $46.4M; cash $7.6M; PDUFA Aug 27

## Summary
- Net loss $46.4M ($1.50/share) vs $114.3M ($8.01) YoY; adjusted net loss $12.5M ($0.40) vs $22.1M ($1.55).
- Cash and equivalents $7.6M as of March 31, 2025; no revenue (pre-commercial stage).
- LYTENAVA commercial launch in Germany and UK planned for Q2 CY2025.
- FDA PDUFA goal date August 27, 2025 for ONS-5010 (bevacizumab-vikg) BLA resubmission.
- Warrant inducement expenses $33.9M and other non-cash items drove adjusted loss items.

## SEC filing metadata
- accession: 0001104659-25-049411
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/0001104659-25-049411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/tm2515284d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-049411
- JSON: https://secwatch.observer/filing/0001104659-25-049411.json
- Plain text: https://secwatch.observer/filing/0001104659-25-049411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.